According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “
A number of other analysts also recently issued reports on the stock. Morgan Stanley increased their target price on shares of ZEALAND PHARMA/S from $29.00 to $30.00 and gave the stock an overweight rating in a research report on Monday, August 19th. TheStreet cut shares of ZEALAND PHARMA/S from a c rating to a d+ rating in a research report on Friday, August 16th. Finally, Needham & Company LLC reiterated a buy rating and set a $32.00 price objective (up from $29.00) on shares of ZEALAND PHARMA/S in a research note on Thursday, August 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. ZEALAND PHARMA/S has an average rating of Hold and a consensus target price of $27.33.
Shares of ZEAL opened at $23.50 on Friday. The firm has a market cap of $715.87 million, a PE ratio of 7.83 and a beta of 1.98. The company’s fifty day moving average is $21.63 and its two-hundred day moving average is $19.95. ZEALAND PHARMA/S has a fifty-two week low of $11.51 and a fifty-two week high of $23.84.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.10). The firm had revenue of $3.00 million during the quarter, compared to analyst estimates of $7.50 million. Equities research analysts anticipate that ZEALAND PHARMA/S will post -2.22 EPS for the current year.
A hedge fund recently raised its stake in ZEALAND PHARMA/S stock. Farallon Capital Management LLC increased its stake in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) by 5.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,000,000 shares of the company’s stock after acquiring an additional 51,300 shares during the period. Farallon Capital Management LLC owned approximately 3.25% of ZEALAND PHARMA/S worth $21,550,000 at the end of the most recent reporting period. Institutional investors own 9.38% of the company’s stock.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Recommended Story: Why do companies engage in swaps?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.